MCO-010 improves vision in retinitis pigmentosa through 4 years
NEW ORLEANS — An optogenetic therapy helped patients with retinitis pigmentosa maintain vision gains through 4 years, according to a study presented at the American Academy of Ophthalmology meeting.
“Optogenetics is a huge future potential for patients with low vision and irreversible vision loss,” Kenneth C. Fan, MD, MBA, of Retina Consultants of Texas, told Healio. “Retinitis pigmentosa causes slow, progressive vision loss over time. Patients are often legally blind in their 30s and 40s, so it’s a very tragic disease with no current treatment.”
{{VIDEO}}
Fan said REMAIN is the long-term